Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.

JAK inhibitors show promise for treating skin diseases effectively and safely.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

A cancer patient's hair became permanently curly after treatment with nivolumab.

Salivary vitamin D and IL-6 could help diagnose and manage non-scarring alopecia.

LL-37 helps stem cells grow and move, aiding tissue regeneration and hair growth.

Alopecia areata patients have higher levels of IL-6 and TNF-α.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Blocking IL-17a can improve age-related smell loss in mice.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

New treatments like PBMC, G-CSF, and PRP show promise for helping with repeated implantation failure.

IFNγ-primed MSC secretomes can improve joint health by reducing inflammation and supporting tissue repair.

Bimekizumab effectively treated a man's chronic beard hair loss.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

CD18-deficient mice developed psoriasis-like skin disease, useful for studying inflammatory skin disorders.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Canakinumab's effect on COVID-19 outcomes is unclear.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.